BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Ariana Pharma Collaborates With Fovea Pharmaceuticals On Phase II Clinical Data Analysis


2/4/2010 3:16:49 PM

Paris, February 4, 2010 - Ariana(R) Pharma, a provider of decision support tools and services to accelerate drug discovery and development, announces today that it has won a significant fee for service collaboration deal with Fovea Pharmaceuticals. Under the terms of the collaboration, Ariana(R) deploys its KEM(R) (Knowledge Extraction and Management) decision support platform to carry out systematic analysis of Fovea's Prednisporin(TM) Phase II clinical data, in order to optimize clinical design and maximize the probability of successful further development of this drug. Financial terms were not disclosed.

The current collaboration is based on the use of KEM Clinicals, a new version of its successful decision support platform, KEM(R), dedicated to supporting the clinical development and safety process. In addition to comprehensive systematic analysis and the design benefits, KEM Clinicals also helps better define patients who will benefit from the product.

"The collaboration with Fovea Pharmaceuticals, a leading biotech specialized in ocular diseases, is very important to Ariana(R) Pharma as it demonstrates that KEM(R) is not only dedicated to large pharma companies but can bring significant help to smaller biotech companies to speed up and secure their clinical trial designs," said Mohammad Afshar, CEO of Ariana(R) Pharma.

About Arian(R) Pharma http://www.arianapharma.com/

Ariana(R) Pharma delivers pioneering multi objectives decision support tools to dramatically accelerate and improve the discovery, development and safety of pharmaceutical products. Its KEM(R) knowledge extraction and management platform comprehensively mines data, including data other systems neglect, and helps scientists take simultaneous decisions involving multiple criteria and objectives. The company has established a rapidly growing software business through collaboration and licensing agreements with some of the largest pharmaceutical and biotechnology companies. Ariana(R) was founded in 2003 and is headquartered in Paris, France.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES